Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Investor Presentation (November 2017)
19 slides from Cynata Therapeutics's investor presentation, Nov 15, 2017
Slide 1: ASX Announcement: Company Investor Presentation
ASX ANNOUNCEMENT 15 November 2017 For personal use only Company Investor Presentation Melbourne, Australia; 15 November 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to release a new investor presentation to be presented at a series
Slide 2: About Cynata Therapeutics (ASX: CYP)
About Cynata Therapeutics (ASX: CYP) For personal use only Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical stage stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison
Slide 3: A Next Generation Stem Cell Company
For personal use only A Next Generation Stem Cell Company Investor Presentation Cynata Therapeutics Limited November 2017
Slide 4: Important Information
Important Information This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necess
Slide 5: Investment overview
Investment overview For personal use only Unique technology to efficiently mass-produce mesenchymal stem cells (MSCs), 1 a highly promising type of therapeutic stem cell World first clinical trial, going from concept to clinic in less than 4 years & providing 2 a springboard for further clinical stu
Slide 6: Corporate overview: A biotech company with a world-first clinical trial
Corporate overview: A biotech company with a world-first clinical trial and leading technology platform For personal use only Company profile 6 month share price performance Cynata Therapeutics is an Australian clinical-stage biotechnology company developing disruptive Price (A$) Volume (k) regene
Slide 7: Cynata Therapeutics is at an inflection point as it accelerates clinical testing
Cynata Therapeutics is at an inflection point as it accelerates clinical testing For personal use only May 15 May 16 Jan 17 Mar 17 NOW... Cymerus platform License option Strategic Successful successfully agreement with partnership and evaluation of Patient dosing validated in a GMP apceth $4m invest
Slide 8: Why MSCs?
Why MSCs? For personal use only What are MSCs? CD4+ T Lymphocyte CD8+ T Lymphocyte • Mesenchymal stem cells (MSCs) are highly potent adult stem cells found in ϒδ T Cell bone marrow and certain other tissues. NK Cell What do they do? HLA-G5 • They have the ability to self renew. IDO, iNOS, HO1 PGE2 T
Slide 9: Only company in the world with a platform to mass-produce MSCs without multiple donors
Only company in the world with a platform to mass-produce MSCs without multiple donors For personal use only First generation process has multiple shortcomings Donation taken Purified MSCs then massively Therapeutic MSCs through a complex expanded to provide are administered to Inconsistent product
Slide 10: Regenerative medicine market growing rapidly and MSCs are a major growth driver
Regenerative medicine market growing rapidly and MSCs are a major growth driver For personal use only How big is the market for regenerative medicine? “Global regenerative medicine market was worth $18.9 billion in 2016 and will grow to over $53.7 billion by 20211” “Stem cells are the cornerstone of
Slide 11: Cynata is operating in a highly active market
Cynata is operating in a highly active market Cellular therapy is a key category and no longer an evolving market For personal use only August: US FDA approved Novartis’ product, Kymriah, a T cell (CAR-T) treatment for leukemia August: Gilead to acquire Kite Pharma for US$11.9b. Kite develops simila
Slide 12: Our platform provides a scalable business model
Our platform provides a scalable business model, applicable to a broad range of disease targets For personal use only Vigorous Ongoing External Early monetisation partner revenue collaborations via multiple revenue engagement stream streams Phase: Pre-clinical Phase I, II, III Market What: Develop
Slide 13: Progress made against business model
Progress made against business model External Vigorous partner Further For personal use only collaborations engagement revenues Pre-clinical Proof of Clinical Deal Product in- Disease target area trials concept trial Key highlights secured market started completed started Graft v Host Disease (GvHD)
Slide 14: Business is focused on progressing the world-first clinical trial of CYP-001 in GvHD
Business is focused on progressing the world- first clinical trial of CYP-001 in GvHD For personal use only CymerusTM MSCs demonstrated a significant survival benefit in Pre-clinical Completed a pre-clinical rodent model of Graft vs. Host Disease License option agreement secured with Fujifilm, inclu
Slide 15: GvHD was the optimal first target area
GvHD was the optimal first target area for several medical and commercial reasons For personal use only MSCs have already shown to be an effective treatment against GvHD In Japan MSCs have been approved for use as a treatment for GvHD Short trial duration, with expected completion in early 2018
Slide 16: Fujifilm has demonstrated confidence in Cynata's platform through a licensing agreement
Fujifilm has demonstrated confidence in Cynata’s platform through a licensing agreement for GvHD For personal use only is one of the largest License overview: Development and global investors in regenerative medicine commercialisation of Cynata’s MSCs for GvHD 2014: Fujifilm takes a controlling st
Slide 17: Board and management overview
Board and management overview For personal use only Dr Paul Wotton Dr Ross Macdonald Dr Stewart Washer Dr John Chiplin Mr Peter Webse Dr Kilian Kelly Chairman Managing Director Non-Executive Non-Executive Non-Executive Director Vice President, Chief Executive Officer Director Director Company Secret
Slide 18: Investment Summary
Investment Summary For personal use only Scalable, world-first technology: Cymerus platform overcomes inherent challenges of other production methods, and enables mass-production of therapeutic MSCs Technology already being monetised: Licensing agreements with Fujifilm and apceth Biopharma. Fuji
Slide 19: Thank you for your attention
For personal use only Thank you for your attention Cynata Therapeutics Limited Contact details: Level 3 ross.macdonald@cynata.com 62 Lygon Street Carlton +61 (0) 412 119343 Victoria 3053 www.cynata.com Australia 17
Cynata Therapeutics — Investor Presentation (November 2017) on 6ix